Barrett's Esophagus With High-Grade Dysplasia: Chemoprevention Alongside Ablation
With high-grade dysplasia confirmed and endoscopic ablation no longer a real point of disagreement, the actual question left on the table is whether to add aspirin to high-dose PPI therapy around the ablation itself — the same chemoprevention question as non-dysplastic and low-grade Barrett's, but at meaningfully higher stakes.
Nathaniel P., 64, retired from the fire department two years ago and now spends most of his time restoring an old sailboat with his son-in-law, a project he describes with the same careful, methodical patience he says kept him steady through thirty years of emergency calls. His Barrett's esophagus was found eleven years ago and had remained non-dysplastic on annual surveillance until this year, when a new nodular area was identified and biopsied, confirmed as high-grade dysplasia by two independent GI pathologists after endoscopic mucosal resection of the visible lesion. Unlike the lower-stakes version of this same disease seen at earlier stages, HGD carries a substantial enough progression risk to esophageal adenocarcinoma that endoscopic ablation of the remaining Barrett's segment isn't really a contested decision here — every voice at this table agrees on it.
What remains genuinely open is the same chemoprevention question that comes up at every stage of Barrett's disease, aspirin added to high-dose PPI therapy, but at meaningfully higher stakes now that the diagnosis is HGD rather than non-dysplastic or low-grade disease. The trial evidence behind aspirin's role, drawn primarily from AspECT and similar work across the broader Barrett's population, wasn't specifically powered to isolate its effect in an HGD subgroup this advanced, and post-ablation patients also carry a real, if generally modest, bleeding risk from the treated mucosa during the healing interval — a window where adding an antiplatelet agent is a genuinely different calculation than adding it to an intact, non-dysplastic esophagus.
That window has been measured: published post-ablation series report clinically significant bleeding in a small but real minority of cases, concentrated in the first one to two weeks after treatment while the ablated mucosa is actively re-epithelializing — a defined, time-limited window rather than an open-ended concern, which is exactly why "hold until confirmed healing" is a specific, dateable plan rather than an indefinite deferral of a decision the gastroenterologist still believes is worth making sooner.
The uncontested decision and the one still open
Ablation isn't in question here — his HGD is confirmed by two pathologists, and the progression risk is real enough that every one of us agrees on that part. What I'd push on is aspirin: if AspECT showed a composite risk reduction in the broader Barrett's population, a patient at his elevated risk level arguably has more to gain from it, not less. I'd add it now, alongside the PPI increase, rather than wait.
I'd hold aspirin until after ablation and confirmed healing. The freshly-treated mucosa carries a real, if generally modest, bleeding risk during that interval, and that's a genuinely different, more immediate consideration than the chemoprevention question AspECT was actually built around. That trial wasn't specifically powered to isolate a benefit in a population this advanced or this soon after an endoscopic procedure.
I'm not disputing that his elevated risk level is a real reason to want aspirin eventually — I'm arguing the timing matters more here than it did in the non-dysplastic version of this same conversation.
I'd support holding aspirin until healing is confirmed, and I want us to document why explicitly rather than treat this as the same conversation we'd have with a non-dysplastic patient. His situation is meaningfully different — higher progression risk, but also a fresh ablation site with its own bleeding risk — and both of those deserve to be named on their own terms rather than folded automatically into an earlier discussion's conclusion.
Agreed: PPI increased to high-dose therapy immediately, ablation scheduled without delay given the confirmed HGD diagnosis, and aspirin held until endoscopic confirmation of mucosal healing at the post-ablation follow-up rather than started concurrently.
Not fully agreed: the gastroenterologist's view that his elevated progression risk argued for starting aspirin sooner rather than later. That position wasn't overruled so much as outweighed, for now, by the more immediate and better-characterized bleeding risk of the freshly-ablated segment — a decision explicitly documented as specific to his HGD-and-post-ablation situation, not a general rule for lower-risk Barrett's patients.